Diabetes Education News

ATLANTA — Adults with obesity, HF with preserved ejection fraction and type 2 diabetes saw marked improvements in HF symptoms and physical function with semaglutide 2.4 mg compared with placebo, despite less than typical weight loss.

Adults with type 2 diabetes have a reduction in overall health care costs after bariatric surgery, regardless of whether they underwent gastric bypass or sleeve gastrectomy, according to study findings published in Obesity.

Prices for most diabetes medications exceed their manufacturing costs, and the addition of generic or biosimilar medications could help to lower prices, according to study findings published in JAMA Network Open.

Hybrid closed-loop insulin delivery systems are more cost-effective for treating type 1 diabetes than immune therapies unless the effects of immune therapies are persistent over a lifetime after one course, according to a speaker.

Adults with diabetes who are forced to switch to a high-deductible health insurance plan have higher risk for diabetes-related complications than those who remain on a regular health plan, according to study data.

Neighborhoods that were historically redlined on Home Owners’ Loan Corporation maps in the 1930s are associated with higher diabetes prevalence than non-redlined areas after adjusting for 2010 population figures, according to study data.

Pregnant women with type 1 diabetes achieved a higher time in range and had fewer complications with use of a hybrid closed-loop insulin delivery system compared with continuous glucose monitoring alone, according to a speaker.

Susan Weiner, MS, RDN, CDCES, FADCES, talks with Lauren Plunkett, RDN, LD, CDCES, about benefits of plant-based nutrition for people with diabetes and strategies for incorporating whole foods and plants into eating plans.

A once-weekly basal insulin conferred similar changes in HbA1c and time in range as once-daily insulin glargine among adults with type 1 and type 2 diabetes in three phase 2 trials, according to a speaker.

The FDA granted 510(k) clearance for an automated insulin delivery system that can measure the volume and flow of insulin within every micro-dose, according to an industry press release.